Quantcast
Viewing all articles
Browse latest Browse all 3347

Ascletis’ not-so-great weight loss data; Vivace’s $35M Series D

Plus, news about Harbour BioMed: Ascletis’ muscle-preserving drug yields limp weight loss data: The Hong Kong-based biotech said its adipose-targeted obesity therapy, called ASC47, demonstrated placebo-adjusted weight loss of 1.7% 50 ...

Viewing all articles
Browse latest Browse all 3347

Trending Articles